Robert Avery, MD
Retina Specialist · Santa Barbara, CANPI 1700985496
Payments from drug & device makers
Across 344 payments — averaging $553.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$63K
- Genentech, Inc.$31K
- Coherus Oncology, Inc.$14K
- AbbVie$13K
- Bausch & Lomb Americas Inc.$13K
- Ocular Therapeutix, Inc.$12K
- plus $44K from 26 others
Across 19 payments — averaging $847.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$16K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 72 | $63,186 |
| Genentech, Inc. | 20 | $31,027 |
| Coherus Oncology, Inc. | 10 | $14,436 |
| AbbVie(2 entities) | 45 | $12,882 |
| Bausch & Lomb Americas Inc. | 19 | $12,809 |
| Ocular Therapeutix, Inc. | 18 | $11,696 |
| Alcon Research LLC | 3 | $10,187 |
| US Retina LLC | 9 | $9,283 |
| Regeneron Healthcare Solutions, Inc. | 41 | $6,265 |
| Apellis Pharmaceuticals, Inc. | 28 | $3,929 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $3,234 |
| F. Hoffmann-la Roche AG | 1 | $2,250 |
| Oyster Point Pharma, Inc. | 2 | $2,142 |
| Eyepoint US, Inc. | 4 | $1,947 |
| Alcon | 14 | $1,734 |
| Astellas Pharma US Inc | 16 | $774 |
| Regeneron | 8 | $607 |
| Harrow Eye, LLC | 7 | $439 |
| Novartis | 4 | $272 |
| Sight Sciences, Inc. | 2 | $240 |
| Alimera Sciences, Inc. | 4 | $179 |
| Biogen | 2 | $150 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $123 |
| Dompe US, Inc. | 1 | $111 |
| Dutch Ophthalmic, USA | 1 | $107 |
| Neurotech Pharmaceuticals, Inc. | 1 | $101 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Glaukos Corporation | 1 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| GSK | 1 | $20 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$190,289 in reported general payments places this provider in the 80th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Santa Barbara
- Dante PieramiciSanta Barbara$15.1M
- Dilsher DhootSanta Barbara$8.2M
- Nathan SteinleSanta Barbara$2.6M
- Alessandro CastellarinSanta Barbara$1.1M
- Nika BagheriSanta Barbara$528K
- Stephen CouvillionSanta Barbara$361K
- Daniel LearnedSanta Barbara$146K
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.